Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis
Authors
Keywords
Pazopanib, Hypertension, Tyrosine kinase inhibit, Meta-analysis
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 71, Issue 2, Pages 431-439
Publisher
Springer Nature
Online
2012-11-20
DOI
10.1007/s00280-012-2025-5
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Anti-VEGF/VEGFR Therapy for Cancer: Reassessing the Target
- (2012) B. Sitohy et al. CANCER RESEARCH
- An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer
- (2012) Thomas Powles et al. EUROPEAN JOURNAL OF CANCER
- Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
- (2012) Winette TA van der Graaf et al. LANCET
- Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial
- (2012) Andrea Necchi et al. LANCET ONCOLOGY
- Concise Drug Review: Pazopanib and Axitinib
- (2012) R. M. J. M. van Geel et al. ONCOLOGIST
- Meta-analysis of incidence of rare events
- (2012) Peter W Lane STATISTICAL METHODS IN MEDICAL RESEARCH
- Sunitinib and other targeted therapies for renal cell carcinoma
- (2011) T Powles et al. BRITISH JOURNAL OF CANCER
- A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma
- (2011) Wan-Teck Lim et al. CLINICAL CANCER RESEARCH
- A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study
- (2011) J E Ward et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Long-term safety of sorafenib in advanced renal cell carcinoma: Follow-up of patients from phase III TARGET
- (2010) Thomas E. Hutson et al. EUROPEAN JOURNAL OF CANCER
- Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis
- (2010) Mao Mao An et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
- (2010) Michael Friedlander et al. GYNECOLOGIC ONCOLOGY
- Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non–Small-Cell Lung Cancer
- (2010) Nasser Altorki et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of Arterial Thromboembolic Events With Sunitinib and Sorafenib: A Systematic Review and Meta-Analysis of Clinical Trials
- (2010) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II, Open-Label Study of Pazopanib or Lapatinib Monotherapy Compared With Pazopanib Plus Lapatinib Combination Therapy in Patients With Advanced and Recurrent Cervical Cancer
- (2010) Bradley J. Monk et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial
- (2010) Cora N. Sternberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study
- (2010) Keith C Bible et al. LANCET ONCOLOGY
- Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02)
- (2010) F. M. Iwamoto et al. NEURO-ONCOLOGY
- A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium
- (2010) S. K. Taylor et al. ONCOLOGIST
- Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer
- (2009) A. Ravaud et al. ANNALS OF ONCOLOGY
- Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
- (2009) Stefan Sleijfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and Safety of Pazopanib in Patients With Metastatic Renal Cell Carcinoma
- (2009) Thomas E. Hutson et al. JOURNAL OF CLINICAL ONCOLOGY
- Pazopanib
- (2009) Ronald M. Bukowski et al. NATURE REVIEWS DRUG DISCOVERY
- Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: Systematic review and meta-analysis
- (2008) Xiaolei Zhu et al. ACTA ONCOLOGICA
- Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis
- (2008) Shenhong Wu et al. LANCET ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started